Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma

BACKGROUND: Nivolumab plus ipilimumab improves overall survival and is associated with less toxicity compared with sunitinib in the first-line setting of advanced renal-cell carcinoma (RCC). The current study aimed to assess the cost-effectiveness of nivolumab plus ipilimumab for first-line treatmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Bin, Zhang, Qiang, Sun, Jie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247499/
https://www.ncbi.nlm.nih.gov/pubmed/30458884
http://dx.doi.org/10.1186/s40425-018-0440-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6247499/
https://www.ncbi.nlm.nih.gov/pubmed/30458884
http://dx.doi.org/10.1186/s40425-018-0440-9

Ejemplares similares